Payment overview · 2025
General Payments
$416.09
33 reported records · 11 companies
Healthcare provider profile · identity verified
Benjamin Henry Morgan, DO
Allopathic & Osteopathic Physicians|Family Medicine · GREENEVILLE, TN · NPI 1861888927
Verified facts
What the public records show
CMS Open Payments records show Benjamin Henry Morgan, DO received $416.09 in general payments during 2025 across 33 reported records.
ABBVIE INC. accounted for 35.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $147.14 | 35.4% | 18 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $55.21 | 13.3% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $42.38 | 10.2% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.75 | 7.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.31 | 7.3% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.42 | 5.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $22.97 | 5.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.29 | 4.2% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.35 | 3.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.27 | 3.7% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $14.00 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $416.09 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $118.61 | 12 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $95.67 | 10 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $42.38 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $35.87 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $35.87 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $32.75 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.31 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.31 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $28.53 | 6 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $23.42 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $22.97 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.29 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.27 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.27 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $14.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 81 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
81 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 298 | 46 |
| Atorvastatin Calcium | Atorvastatin Calcium | 288 | 82 |
| Lisinopril | Lisinopril | 284 | 79 |
| Levothyroxine Sodium | Levothyroxine Sodium | 212 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 211 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 199 | 55 |
| Losartan Potassium | Losartan Potassium | 139 | 44 |
| Omeprazole | Omeprazole | 135 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 134 | 42 |
| Famotidine | Famotidine | 132 | 41 |
| Jardiance | Empagliflozin | 124 | 30 |
| Metformin Hcl Er | Metformin Hcl | 118 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 116 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 112 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 111 | 38 |
| Metformin Hcl | Metformin Hcl | 99 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 97 | 32 |
| Trazodone Hcl | Trazodone Hcl | 88 | 34 |
| Ozempic | Semaglutide | 81 | 19 |
| Furosemide | Furosemide | 79 | 25 |
| Eliquis | Apixaban | 77 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 69 | 22 |
| Sertraline Hcl | Sertraline Hcl | 68 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 67 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 65 | 16 |
| Tramadol Hcl | Tramadol Hcl | 65 | 12 |
| Meloxicam | Meloxicam | 63 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 33 |
| Glipizide Er | Glipizide | 58 | 18 |
| Bupropion Xl | Bupropion Hcl | 56 | 15 |
| Carvedilol | Carvedilol | 53 | 16 |
| Montelukast Sodium | Montelukast Sodium | 52 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 16 |
| Simvastatin | Simvastatin | 50 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 49 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 12 |
| Trulicity | Dulaglutide | 48 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 46 | 11 |
| Potassium Chloride | Potassium Chloride | 43 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 41 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Ondansetron Odt | Ondansetron | 39 | 21 |
| Pregabalin | Pregabalin | 39 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 14 |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Alprazolam | Alprazolam | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | suppressed |
| Lorazepam | Lorazepam | 30 | suppressed |
| Allopurinol | Allopurinol | 28 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 25 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | 11 |
| Baclofen | Baclofen | 24 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 23 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 23 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 18 |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Prednisone | Prednisone | 20 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Naproxen | Naproxen | 15 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $416.09 · 33 records | ABBVIE INC. | AREXVY, CAPLYTA, GVOKE HYPOPEN, IBSRELA, NUZYRA, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, YUPELRI | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error